Moreover, treatment with recombinant human IL37 suppresses lipopolysaccharide (LPS)-induced cytokines IL1-β, IL6, and tumor necrosis factor (TNF)-α; inhibits p38 mitogen-activated protein kinase (MAPK) activation in M1-differentiated human blood macrophages; and reduces innate inflammation markers in mice subjected to endotoxemia [23]. This evidence concerns the gene TNF and serum lipopolysaccharide activity.